Human CMV (HCMV) achieves persistence in part through the ability to establish latent infections in CD34+ hematopoietic progenitor cells (HPCs) and CD14+ monocytes (1, 2). The gene discussed is CD34; the disease is disease arising from reactivation of latent virus.